How can we, humans, look at our relationship to nature differently? In season three of Going Wild, on top of stories about animals, we invite you to journey through the entire ecological web — from the tiniest of life forms to apex predators — alongside the scientists, activists and adventurers who study it. Wildlife biologist and host Dr. Rae Wynn-Grant has been studying wild animals in their natural habitats all over the world for years. Our award-winning podcast takes you inside the hidde ...
…
continue reading
Innehåll tillhandahållet av Sano Genetics. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Sano Genetics eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Player FM - Podcast-app
Gå offline med appen Player FM !
Gå offline med appen Player FM !
EP 112: Making the leap: the scientists collaborating to transform genetic targets into next generation treatments, with David Ochoa
MP3•Episod hem
Manage episode 385370197 series 2631947
Innehåll tillhandahållet av Sano Genetics. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Sano Genetics eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
This week on The Genetics Podcast Patrick is joined by David Ochoa, Platform Coordinator at Open Targets. They discuss how the Open Targets platform is enabling game-changing collaboration between academic research and big pharma. Working with partners including Sanofi, GlaxoSmithKline, Bristol Myers Squibb, Genentech and Pfizer, Open Targets powers collaboration between some of the world’s biggest drug development pioneers and most renowned academic institutions with the goal of accelerating production of effective drug treatments.
But while the pre competitive approach enables huge time and money savings for all stakeholders, it relies on effective coordination and alignment - David explains how Open Targets tackles the inherent challenges to allow this world-leading consortium to build the future of next generation treatments.
00:03 Introduction
But while the pre competitive approach enables huge time and money savings for all stakeholders, it relies on effective coordination and alignment - David explains how Open Targets tackles the inherent challenges to allow this world-leading consortium to build the future of next generation treatments.
00:03 Introduction
04:33 The types of data sets used for target discovery
08:08 Managing the heterogeneity of data sets
13:29 David Ochoa's career trajectory, and entry into Open Targets
18:28 Addressability of diseases and targets by different modalities
22:24 Retrospective analysis of genetic evidence in drug approvals
36:58 Future focus on revamping Open Targets genetics
39:54 Exploring somatic variation and mutational scanning
42:49 Clinical trial stoppage
48:22 Closing remarks
187 episoder
MP3•Episod hem
Manage episode 385370197 series 2631947
Innehåll tillhandahållet av Sano Genetics. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Sano Genetics eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
This week on The Genetics Podcast Patrick is joined by David Ochoa, Platform Coordinator at Open Targets. They discuss how the Open Targets platform is enabling game-changing collaboration between academic research and big pharma. Working with partners including Sanofi, GlaxoSmithKline, Bristol Myers Squibb, Genentech and Pfizer, Open Targets powers collaboration between some of the world’s biggest drug development pioneers and most renowned academic institutions with the goal of accelerating production of effective drug treatments.
But while the pre competitive approach enables huge time and money savings for all stakeholders, it relies on effective coordination and alignment - David explains how Open Targets tackles the inherent challenges to allow this world-leading consortium to build the future of next generation treatments.
00:03 Introduction
But while the pre competitive approach enables huge time and money savings for all stakeholders, it relies on effective coordination and alignment - David explains how Open Targets tackles the inherent challenges to allow this world-leading consortium to build the future of next generation treatments.
00:03 Introduction
04:33 The types of data sets used for target discovery
08:08 Managing the heterogeneity of data sets
13:29 David Ochoa's career trajectory, and entry into Open Targets
18:28 Addressability of diseases and targets by different modalities
22:24 Retrospective analysis of genetic evidence in drug approvals
36:58 Future focus on revamping Open Targets genetics
39:54 Exploring somatic variation and mutational scanning
42:49 Clinical trial stoppage
48:22 Closing remarks
187 episoder
Όλα τα επεισόδια
×Välkommen till Player FM
Player FM scannar webben för högkvalitativa podcasts för dig att njuta av nu direkt. Den är den bästa podcast-appen och den fungerar med Android, Iphone och webben. Bli medlem för att synka prenumerationer mellan enheter.